Production (Stage)
LENZ Therapeutics, Inc.
LENZ
$31.96
$1.665.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.55% | -23.86% | 0.38% | 38.41% | 29.73% |
| Total Depreciation and Amortization | 44.00% | 150.00% | -44.44% | 260.00% | 25.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 577.03% | -73.32% | 30.41% | -62.89% | 756.11% |
| Change in Net Operating Assets | -189.24% | 375.41% | 80.51% | 31.24% | -402.45% |
| Cash from Operations | -76.79% | 14.20% | 33.01% | 34.01% | -14.15% |
| Capital Expenditure | 26.17% | 19.89% | -39.85% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 262.19% | 81.12% | 36.86% | -645.87% | 18.63% |
| Cash from Investing | 259.23% | 80.94% | 36.76% | -646.61% | 18.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -16.98% | -99.82% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 99.35% | -101.69% | 6,246.05% |
| Cash from Financing | -16.98% | -99.82% | 1,495.32% | -101.25% | 9,062.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.81% | 51.41% | 63.04% | -170.36% | 2,244.93% |